Current Drug Safety

Scope & Guideline

Exploring Innovations in Pharmacology and Toxicology

Introduction

Welcome to your portal for understanding Current Drug Safety, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1574-8863
PublisherBENTHAM SCIENCE PUBL
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCURR DRUG SAF / Curr. Drug Saf.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 294, BUSUM 1400 AG, NETHERLANDS

Aims and Scopes

Current Drug Safety focuses on the exploration, analysis, and reporting of drug safety profiles, adverse drug reactions (ADRs), and pharmacovigilance practices. The journal aims to provide a platform for sharing knowledge and findings related to drug safety, with an emphasis on clinical implications and real-world applications.
  1. Pharmacovigilance and Drug Safety Monitoring:
    The journal emphasizes the systematic monitoring of drug effects, including the identification and reporting of adverse drug reactions, ensuring patient safety in clinical settings.
  2. Case Reports and Literature Reviews:
    Current Drug Safety publishes detailed case reports and comprehensive literature reviews that highlight unique or severe drug reactions, offering insights into clinical management and therapeutic implications.
  3. Clinical Studies and Observational Research:
    The journal supports the publication of observational studies and cohort analyses that provide valuable data on the safety and efficacy of drugs in diverse patient populations.
  4. Drug Interactions and Treatment Protocols:
    Research focusing on drug-drug interactions, treatment efficacy, and safety assessments of drug combinations is a key area of interest, reflecting the complexities of modern pharmacotherapy.
  5. Public Health and Policy Implications:
    The journal discusses the broader implications of drug safety on public health and medication policies, aiming to inform healthcare practitioners and policymakers.
Current Drug Safety has seen a rise in several emerging themes that reflect the evolving landscape of drug safety research. These trends indicate a growing awareness of complex interactions and the need for comprehensive safety assessments in various contexts.
  1. Adverse Drug Reactions Related to COVID-19 Vaccines:
    Research related to the safety profiles and adverse effects of COVID-19 vaccines has gained significant prominence, highlighting the ongoing need for vigilance in vaccination programs.
  2. Drug-Drug Interactions in Polypharmacy:
    With the increasing prevalence of polypharmacy, there is a marked rise in studies addressing drug-drug interactions, especially in vulnerable populations such as the elderly.
  3. Patient Engagement in ADR Reporting:
    Emerging studies focus on enhancing patient engagement in reporting adverse drug reactions, utilizing novel approaches to improve pharmacovigilance practices.
  4. Long-term Safety Monitoring of Biologics and Biosimilars:
    There is a growing emphasis on the long-term safety and efficacy of biologic therapies and their biosimilars, particularly in chronic conditions like autoimmune diseases.
  5. Real-World Evidence and Observational Studies:
    The trend towards utilizing real-world evidence to assess drug safety and efficacy is increasing, reflecting a shift from controlled clinical trials to observational research that captures diverse patient experiences.

Declining or Waning

In recent years, certain themes within Current Drug Safety have shown a decline in focus or frequency of publication. This shift may reflect changing priorities in drug safety research or a saturation of previously explored topics.
  1. Traditional Pharmacology Studies:
    There has been a noticeable decrease in the publication of traditional pharmacology studies that primarily focus on drug mechanisms without addressing safety or adverse effects.
  2. General Drug Efficacy Studies:
    Research solely centered on the efficacy of medications, without a clear link to safety outcomes or adverse drug reactions, has decreased, signaling a shift towards a more safety-centric approach.
  3. Herbal and Alternative Medicine Studies:
    While still relevant, the focus on the safety profiles of herbal and alternative medications appears to be waning, perhaps due to the increasing emphasis on evidence-based practices in conventional pharmacotherapy.

Similar Journals

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Enhancing Understanding of Pharmacological Treatments and Toxicology
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Bridging the Gap Between Science and Healthcare
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

INDIAN JOURNAL OF PHARMACOLOGY

Connecting academia and industry to shape the future of pharmacology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

Therapeutic Advances in Drug Safety

Elevating Patient Care with Cutting-Edge Drug Safety Research
Publisher: SAGE PUBLICATIONS LTDISSN: 2042-0986Frequency: 1 issue/year

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

Safety

Exploring the forefront of public health and safety.
Publisher: MDPIISSN: Frequency: 4 issues/year

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Empowering healthcare through innovative pharmacological research.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

DRUGS & THERAPY PERSPECTIVES

Fostering Excellence in Drug Research and Clinical Applications
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

FARMACIA

Championing Excellence in Pharmacology and Pharmaceutics.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

CLINICAL THERAPEUTICS

Elevating patient care with cutting-edge pharmacological insights.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

European Journal of Hospital Pharmacy

Navigating the Future of Pharmacy in Hospital Settings
Publisher: BMJ PUBLISHING GROUPISSN: 2047-9956Frequency: 6 issues/year

The European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.